Vedolizumab (s) (Serum (s))

sample referred to a partner lab

both sex

No general therapeutic ranges have currently been established for vedolizumab trough levels. Depending on the underlying disease, treatment stage and outcomes, the following threshold values can be recommended: Vendolizumab levels in Crohn`s disease/ulcerative colitis: Induction (week 2) : >= 28 µg/ml for remission Induction (week 6) : >= 24 µg/ml for remission Post-induction (week 14): >= 15 µg/ml for remission and >= 17 µg/ml for mucosal healing. Maintenance : >= 12 µg/ml for remission and >= 14 µg/ml for mucosal healing. The effectiveness of therapy with vedolizumab also depends, among other factors, on the presence of anti-drug antibodies (ADA). In the absence of a clinical response, the following therapeutic decisions can be considered: Trough levels within the recommended range and no evidence of ADA: change outside of drug class. Trough levels below recommended range and evidence of ADA: Optimization of therapy interval/dose and immunomodulation or at higher ADA titers therapy switch within/of drug class. Papamichael K et al. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug? Curr Opin Gastroenterol. 2019 Apr 9